GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zhongyuan Union Cell & Gene Engineering Corp Ltd (SHSE:600645) » Definitions » Piotroski F-Score

Zhongyuan Union Cell & Gene Engineering (SHSE:600645) Piotroski F-Score : 6 (As of Apr. 22, 2025)


View and export this data going back to 1993. Start your Free Trial

What is Zhongyuan Union Cell & Gene Engineering Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Zhongyuan Union Cell & Gene Engineering has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Zhongyuan Union Cell & Gene Engineering's Piotroski F-Score or its related term are showing as below:

SHSE:600645' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 6   Max: 9
Current: 6

During the past 13 years, the highest Piotroski F-Score of Zhongyuan Union Cell & Gene Engineering was 9. The lowest was 2. And the median was 6.


Zhongyuan Union Cell & Gene Engineering Piotroski F-Score Historical Data

The historical data trend for Zhongyuan Union Cell & Gene Engineering's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhongyuan Union Cell & Gene Engineering Piotroski F-Score Chart

Zhongyuan Union Cell & Gene Engineering Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 4.00 8.00 5.00 7.00

Zhongyuan Union Cell & Gene Engineering Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.00 7.00 8.00 5.00 6.00

Competitive Comparison of Zhongyuan Union Cell & Gene Engineering's Piotroski F-Score

For the Biotechnology subindustry, Zhongyuan Union Cell & Gene Engineering's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhongyuan Union Cell & Gene Engineering's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zhongyuan Union Cell & Gene Engineering's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Zhongyuan Union Cell & Gene Engineering's Piotroski F-Score falls into.


;
;

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Net Income was -26.059 + 40.149 + 45.036 + 48.328 = ¥107 Mil.
Cash Flow from Operations was 113.404 + 21.425 + 77.211 + 78.714 = ¥291 Mil.
Revenue was 387.362 + 397.981 + 404.304 + 403.617 = ¥1,593 Mil.
Gross Profit was 262.326 + 274.793 + 279.266 + 287.903 = ¥1,104 Mil.
Average Total Assets from the begining of this year (Sep23)
to the end of this year (Sep24) was
(5422.684 + 5411.355 + 5366.092 + 5309.097 + 5280.484) / 5 = ¥5357.9424 Mil.
Total Assets at the begining of this year (Sep23) was ¥5,423 Mil.
Long-Term Debt & Capital Lease Obligation was ¥76 Mil.
Total Current Assets was ¥2,454 Mil.
Total Current Liabilities was ¥1,482 Mil.
Net Income was -1.564 + 37.374 + 45.301 + 49.837 = ¥131 Mil.

Revenue was 378.671 + 377.745 + 420.328 + 404.289 = ¥1,581 Mil.
Gross Profit was 236.674 + 259.223 + 289.716 + 287.083 = ¥1,073 Mil.
Average Total Assets from the begining of last year (Sep22)
to the end of last year (Sep23) was
(5226.938 + 5284.619 + 5247.792 + 5384.85 + 5422.684) / 5 = ¥5313.3766 Mil.
Total Assets at the begining of last year (Sep22) was ¥5,227 Mil.
Long-Term Debt & Capital Lease Obligation was ¥93 Mil.
Total Current Assets was ¥2,504 Mil.
Total Current Liabilities was ¥1,459 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Zhongyuan Union Cell & Gene Engineering's current Net Income (TTM) was 107. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Zhongyuan Union Cell & Gene Engineering's current Cash Flow from Operations (TTM) was 291. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep23)
=107.454/5422.684
=0.01981565

ROA (Last Year)=Net Income/Total Assets (Sep22)
=130.948/5226.938
=0.02505253

Zhongyuan Union Cell & Gene Engineering's return on assets of this year was 0.01981565. Zhongyuan Union Cell & Gene Engineering's return on assets of last year was 0.02505253. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Zhongyuan Union Cell & Gene Engineering's current Net Income (TTM) was 107. Zhongyuan Union Cell & Gene Engineering's current Cash Flow from Operations (TTM) was 291. ==> 291 > 107 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep23 to Sep24
=76.25/5357.9424
=0.01423121

Gearing (Last Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=92.56/5313.3766
=0.01742018

Zhongyuan Union Cell & Gene Engineering's gearing of this year was 0.01423121. Zhongyuan Union Cell & Gene Engineering's gearing of last year was 0.01742018. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep24)=Total Current Assets/Total Current Liabilities
=2454.434/1481.844
=1.65633764

Current Ratio (Last Year: Sep23)=Total Current Assets/Total Current Liabilities
=2504.139/1458.579
=1.71683467

Zhongyuan Union Cell & Gene Engineering's current ratio of this year was 1.65633764. Zhongyuan Union Cell & Gene Engineering's current ratio of last year was 1.71683467. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Zhongyuan Union Cell & Gene Engineering's number of shares in issue this year was 434.667. Zhongyuan Union Cell & Gene Engineering's number of shares in issue last year was 501.16. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1104.288/1593.264
=0.69309794

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1072.696/1581.033
=0.67847793

Zhongyuan Union Cell & Gene Engineering's gross margin of this year was 0.69309794. Zhongyuan Union Cell & Gene Engineering's gross margin of last year was 0.67847793. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep23)
=1593.264/5422.684
=0.29381465

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep22)
=1581.033/5226.938
=0.30247786

Zhongyuan Union Cell & Gene Engineering's asset turnover of this year was 0.29381465. Zhongyuan Union Cell & Gene Engineering's asset turnover of last year was 0.30247786. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+0+1+1+0
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Zhongyuan Union Cell & Gene Engineering has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Zhongyuan Union Cell & Gene Engineering  (SHSE:600645) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Zhongyuan Union Cell & Gene Engineering Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Zhongyuan Union Cell & Gene Engineering's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhongyuan Union Cell & Gene Engineering Business Description

Traded in Other Exchanges
N/A
Address
45 East of Tianjin Airport Economic Zone nine, Tianjin, CHN, 300304
Zhongyuan Union Cell & Gene Engineering Corp Ltd is engaged in stem cell technology research, as well as detection and storage sources of stem cells in China. The company insists on the core strategy upon dual-core development of 'cell + gene' with the major businesses covering various cell storage businesses of newborns and adults; the preparation and storage of cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, adipose-derived stem cells and immune cells; genetic testing services relating to children's genes.
Executives
Li De Fu Director
Wang Xue Jun senior management
Wang Yong Director
Li Hai Bin Director
He Wei senior management
Li Qiang senior management
Wu Ming Yuan Director
Wang Hui Director
Huang Jia Xue senior management
Cao Hai Feng Director
Han Yue E Director
Liu Yong Jun senior management
Cui Jing Xue Supervisors
Yang Guang Xing senior management
Meng Zhi Hong senior management

Zhongyuan Union Cell & Gene Engineering Headlines

No Headlines